Cargando…

The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study

BACKGROUND: Anatabine (ANA), a minor tobacco alkaloid found in the Solanaceae family of plants, may exhibit anti-inflammatory activity, which may be useful to aid in recovery from exercise-induced muscle damage. The purpose of this study, therefore, was to examine the effects of ANA supplementation...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, Nathaniel DM, Housh, Terry J, Johnson, Glen O, Traylor, Daniel A, Bergstrom, Haley C, Cochrane, Kristen C, Lewis,, Robert W, Schmidt, Richard J, Cramer, Joel T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723652/
https://www.ncbi.nlm.nih.gov/pubmed/23875823
http://dx.doi.org/10.1186/1550-2783-10-33
_version_ 1782278312553349120
author Jenkins, Nathaniel DM
Housh, Terry J
Johnson, Glen O
Traylor, Daniel A
Bergstrom, Haley C
Cochrane, Kristen C
Lewis,, Robert W
Schmidt, Richard J
Cramer, Joel T
author_facet Jenkins, Nathaniel DM
Housh, Terry J
Johnson, Glen O
Traylor, Daniel A
Bergstrom, Haley C
Cochrane, Kristen C
Lewis,, Robert W
Schmidt, Richard J
Cramer, Joel T
author_sort Jenkins, Nathaniel DM
collection PubMed
description BACKGROUND: Anatabine (ANA), a minor tobacco alkaloid found in the Solanaceae family of plants, may exhibit anti-inflammatory activity, which may be useful to aid in recovery from exercise-induced muscle damage. The purpose of this study, therefore, was to examine the effects of ANA supplementation on the recovery of isometric strength and selected non-invasive indicators of muscle damage. METHODS: A double-blinded, placebo-controlled, crossover design was used to study eighteen men (mean ± SD age = 22.2 ± 3.1 yrs; body mass = 80.3 ± 15.7 kg) who participated in two randomly-ordered conditions separated by a washout period. The ANA condition consisted of consuming 6–12 mg anatabine per day for 10 days, while testing took place during days 7–10. The placebo (PLA) condition was identical except that the PLA supplement contained no ANA. Maximal voluntary isometric peak torque (PT) of the forearm flexors, arm circumference, hanging joint angle, and subjective pain ratings were measured before (PRE), immediately after (POST), and 24, 48, and 72 h after six sets of 10 maximal, eccentric isokinetic forearm flexion muscle actions. Resting heart rate and blood pressure were measured at PRE and 72 h in each condition. RESULTS: For PT, hanging joint angle, arm circumference, and subjective pain ratings, there were no condition x time (p > 0.05) interactions, there were no main effects for condition (p > 0.05), but there were main effects for time (p < 0.001). There were no condition x time (p > 0.05) interactions and no main effects for condition (p > 0.05) or time (p > 0.05) for blood pressure or resting heart rate. CONCLUSIONS: ANA supplementation had no effect on the recovery of muscle strength, hanging joint angle, arm swelling, or subjective pain ratings after a bout of maximal eccentric exercise in the forearm flexors. Therefore, ANA may not be beneficial for those seeking to improve recovery from heavy eccentric exercise. Future studies should examine the effects of ANA on the pro-inflammatory cytokine responses to exercise-induced muscle damage and the chronic low-grade inflammation observed in obese and elderly individuals.
format Online
Article
Text
id pubmed-3723652
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37236522013-07-26 The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study Jenkins, Nathaniel DM Housh, Terry J Johnson, Glen O Traylor, Daniel A Bergstrom, Haley C Cochrane, Kristen C Lewis,, Robert W Schmidt, Richard J Cramer, Joel T J Int Soc Sports Nutr Research Article BACKGROUND: Anatabine (ANA), a minor tobacco alkaloid found in the Solanaceae family of plants, may exhibit anti-inflammatory activity, which may be useful to aid in recovery from exercise-induced muscle damage. The purpose of this study, therefore, was to examine the effects of ANA supplementation on the recovery of isometric strength and selected non-invasive indicators of muscle damage. METHODS: A double-blinded, placebo-controlled, crossover design was used to study eighteen men (mean ± SD age = 22.2 ± 3.1 yrs; body mass = 80.3 ± 15.7 kg) who participated in two randomly-ordered conditions separated by a washout period. The ANA condition consisted of consuming 6–12 mg anatabine per day for 10 days, while testing took place during days 7–10. The placebo (PLA) condition was identical except that the PLA supplement contained no ANA. Maximal voluntary isometric peak torque (PT) of the forearm flexors, arm circumference, hanging joint angle, and subjective pain ratings were measured before (PRE), immediately after (POST), and 24, 48, and 72 h after six sets of 10 maximal, eccentric isokinetic forearm flexion muscle actions. Resting heart rate and blood pressure were measured at PRE and 72 h in each condition. RESULTS: For PT, hanging joint angle, arm circumference, and subjective pain ratings, there were no condition x time (p > 0.05) interactions, there were no main effects for condition (p > 0.05), but there were main effects for time (p < 0.001). There were no condition x time (p > 0.05) interactions and no main effects for condition (p > 0.05) or time (p > 0.05) for blood pressure or resting heart rate. CONCLUSIONS: ANA supplementation had no effect on the recovery of muscle strength, hanging joint angle, arm swelling, or subjective pain ratings after a bout of maximal eccentric exercise in the forearm flexors. Therefore, ANA may not be beneficial for those seeking to improve recovery from heavy eccentric exercise. Future studies should examine the effects of ANA on the pro-inflammatory cytokine responses to exercise-induced muscle damage and the chronic low-grade inflammation observed in obese and elderly individuals. BioMed Central 2013-07-22 /pmc/articles/PMC3723652/ /pubmed/23875823 http://dx.doi.org/10.1186/1550-2783-10-33 Text en Copyright © 2013 Jenkins et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jenkins, Nathaniel DM
Housh, Terry J
Johnson, Glen O
Traylor, Daniel A
Bergstrom, Haley C
Cochrane, Kristen C
Lewis,, Robert W
Schmidt, Richard J
Cramer, Joel T
The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study
title The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study
title_full The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study
title_fullStr The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study
title_full_unstemmed The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study
title_short The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study
title_sort effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723652/
https://www.ncbi.nlm.nih.gov/pubmed/23875823
http://dx.doi.org/10.1186/1550-2783-10-33
work_keys_str_mv AT jenkinsnathanieldm theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT houshterryj theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT johnsongleno theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT traylordaniela theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT bergstromhaleyc theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT cochranekristenc theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT lewisrobertw theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT schmidtrichardj theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT cramerjoelt theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT jenkinsnathanieldm effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT houshterryj effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT johnsongleno effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT traylordaniela effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT bergstromhaleyc effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT cochranekristenc effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT lewisrobertw effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT schmidtrichardj effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy
AT cramerjoelt effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy